

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism, characterized in that it comprises~~ comprising pilocarpine combined with at least one bioadhesive polymer so as to allow dissolution and local attachment to the tissues of the buccopharyngeal cavity.

2. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism~~ according to claim 1, wherein the pilocarpine is the basic pilocarpine or pilocarpine in the form of salt, chlorohydrate or nitrate.

3. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism~~ according to claim 1, wherein ~~it~~ the composition is further combined with a mass substrate of the family of soluble carbohydrates with a low molecular weight, glucose or lactose.

4. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism~~ according to claim 1, ~~wherein it comprises at least~~ further comprising a buffer.

5. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein it comprises further~~ comprising at least one lubricant.

6. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein it comprises further~~ comprising at least one softening agent.

7. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism according to claim 1, wherein it comprises further~~ comprising at least one hydrophilic substance.

8. (Currently Amended) ~~Galenical~~ A galenical formulation ~~that includes a comprising the composition according to claim 1, wherein it makes it possible with the pilocarpine: the~~ formulation:

[[-]] makes it possible for the pilocarpine to directly and instantaneously access the muscarine-like receptors of the submucous glandular structures; [[,]]

[[-]] ~~to protect it and~~ protects the pilocarpine to keep it stable with regard to ~~the~~ light, ~~the~~ temperature and ~~the~~ oxidation; [[,]] and

~~[[-]]~~ ~~to allow it~~ allows the pilocarpine to dissolve and to ~~be attached~~ attach locally to tissues of the buccopharyngeal cavity.

9. (Currently Amended) ~~Sublingual~~ A sublingual tablet for the treatment of hyoptyalism, ~~having~~ comprising the pharmaceutical composition according to claim 1, ~~wherein it comprises at least the pilocarpine and at least one bioadhesive polymer.~~

10. (Currently Amended) ~~Sublingual~~ The sublingual tablet ~~for the treatment of hyoptyalism~~ according to claim 9, wherein the bioadhesive polymer is selected from ~~among the family of the~~ group consisting of: cellulose derivatives, gums or polymers of the alginic acid type and derivatives, carboxy-vinyl polymer, carbomer, macrogols, gelatin, povidone, ~~or~~ and pectins.

11. (Currently Amended) ~~Sublingual~~ The sublingual tablet ~~for the treatment of hyoptyalism~~ according to claim 9, wherein ~~it has the following formula~~ the tablet comprises:

~~[[-]]~~ 2.5 mg pilocarpine that is basic or in salt form, ~~[[:]]~~ 2.5 mg

~~[[-]]~~ 10.0 mg magnesium stearate, ~~[[:]]~~ 10.0 mg

~~[[-]]~~ 90.0 mg sodium or disodium hydrogen phosphate, ~~[[:]]~~ 90.0 mg

~~[[-]]~~ 50.0 mg K 100 methocel, ~~[[:]]~~ 50.0 mg

[[-]] ~~6-000-40.0 mg polyethylene glycol, 6000~~[[:]]
~~40.0 mg~~
[[-]] ~~20.0 mg hyaluronic acid,~~[[:]]
~~20.0 mg~~
[[-]] ~~15.0 mg lysozyme chlorohydrate, and~~[[:]]
~~15.0 mg~~
[[-]] ~~772.5 mg compressed sorbitol qsp for 1000~~
mg. [[:]] ~~772.5 mg~~

12. (Currently Amended) ~~Sublingual~~The sublingual tablet for the treatment of hypoptyalism according to claim 11, wherein the sodium or disodium hydrogen phosphate is replaced by sodium carbonate or sodium bicarbonate in the same proportions.

13. (Currently Amended) ~~Pharmaceutical~~The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 2, wherein it comprises at least further comprising a buffer.

14. (Currently Amended) ~~Pharmaceutical~~The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 3, wherein it comprises at least further comprising a buffer.

15. (Currently Amended) ~~Pharmaceutical~~The pharmaceutical composition that is useful as a medicine for the treatment of hypoptyalism according to claim 2, wherein it comprises further comprising at least one lubricant.

16. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism~~ according to claim 3, ~~wherein it comprises~~ further comprising at least one lubricant.

17. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism~~ according to claim 2, ~~wherein it comprises~~ further comprising at least one softening agent.

18. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism~~ according to claim 3, ~~wherein it comprises~~ further comprising at least one softening agent.

19. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition ~~that is useful as a medicine for the treatment of hypoptyalism~~ according to claim 2, ~~wherein it comprises~~ further comprising at least one hydrophilic substance.

20. (Currently Amended) ~~Sublingual~~ The sublingual tablet ~~for the treatment of hypoptyalism~~ according to claim 10, wherein it ~~has the following formula~~ the tablet comprises:

[[-]] 2.5 mg pilocarpine that is basic or in salt form, [[:]] 2.5 mg

[[-]] 10.0 mg magnesium stearate, [[:]]
10.0 mg

[[-]] 90.0 mg sodium or disodium hydrogen
 phosphate, 90.0 mg
 [[-]] 50.0 mg K 100 methocel, 50.0 mg
 50.0 mg
 [[-]] 40.0 mg ~~6-000~~ polyethylene glycol 6000, 40.0 mg
 40.0 mg
 [[-]] 20.0 mg hyaluronic acid, 20.0 mg
 20.0 mg
 [[-]] 15.0 mg lysozyme chlorohydrate, and 15.0 mg
 15.0 mg
 [[-]] 772.5 mg compressed sorbitol qsp for 1000
 mg, 772.5 mg